1. Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol
- Author
-
Parabiaghi, A, Tettamanti, M, D'Avanzo, B, Barbato, A, Aguglia, Eugenio, Bufalino, C, Cannavo', D, Gandolfo, L, Bassi, M, Erlicher, A, Agnetti, G, Breviario, G, Casacchia, M, Pollce, R, Pomero, P, Colotto, A, Manfrinati, S, Cattaneo, Ci, Corrivetti, G, Pinto, G, Ferranini, L, Marcenaro, M, Vaggi, M, Ghio, L, Natta, W, Ferrato, F, Francomano, A, La Placha, M, Mastroeni, A, Rigamonti, D, Groppi, C, Mauri, Mc, De Gaspari IF, Percudanim, Picci, R, Comino, L, Paschetta, E, Pioli, R, Bignotti, S, Smerieri, G, Ghinaglia, Visani, E, Lucattini, A, Caverzasi, E, Colombo, R, Cervetti, A, D'Aloise, A, Parise, Vf, Florio, V, Hadjichristos, A, D'Avamzo, B, Buratti, G, Buratti, L, De Micheli, A, Furlato, K, D'Onofrio, S, Mariannantoni, I, Rapisarda, F, Riccardi, F, Ruberto, A, Ruggirello, I, Santini, I, Trivelli, F, and Ullo, A.
- Subjects
Olanzapine ,Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Aripiprazole ,law.invention ,03 medical and health sciences ,Benzodiazepines ,0302 clinical medicine ,Randomized controlled trial ,law ,Internal medicine ,Haloperidol ,Medicine ,Humans ,Antipsychotic ,Psychiatry ,Adverse effect ,Metabolic Syndrome ,business.industry ,Middle Aged ,medicine.disease ,030227 psychiatry ,Discontinuation ,Psychiatry and Mental health ,Treatment Outcome ,Schizophrenia ,Female ,business ,030217 neurology & neurosurgery ,medicine.drug ,Antipsychotic Agents ,Follow-Up Studies - Abstract
Objective To determine whether the prescription of aripiprazole, compared with olanzapine and haloperidol, was associated with a lower frequency of metabolic syndrome (MS) and treatment discontinuation at 1 year. Method Patients were randomly assigned to be treated open-label and according to usual clinical practice with either aripiprazole, olanzapine, or haloperidol and followed up for 1 year. Results Three hundred out-patients with persistent schizophrenia were recruited in 35 mental health services. The intention-to-treat (ITT) analysis found no significant differences in the rate of MS between aripiprazole (37%), olanzapine (47%), and haloperidol (42%). Treatment discontinuation for any cause was higher for aripiprazole (52%) than for olanzapine (33%; OR, 0.41; P = 0.004), or haloperidol (37%; OR, 0.51; P = 0.030). No significant difference was found between olanzapine and haloperidol. Time to discontinuation for any cause was longer for olanzapine than for aripiprazole (HR, 0.55; P
- Published
- 2015